EyePoint Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Developments
November 01, 2023 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
– Positive masked safety data update for EYP-1901 in ongoing PAVIA and DAVIO 2 Phase 2 clinical trials as of October 1, 2023 with no drug related ocular or systemic SAEs reported – – Leadership...
EyePoint Pharmaceuticals to Host Virtual Key Opinion Leader (KOL) Event on November 9, 2023
October 31, 2023 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients...
EyePoint Pharmaceuticals to Report Third Quarter 2023 Financial Results on November 1, 2023
October 25, 2023 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients...
EyePoint Pharmaceuticals Strengthens Board and Executive Leadership Team
October 16, 2023 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
– Stuart Duty appointed to EyePoint’s Board of Directors – – George Elston promoted to Executive Vice President – WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- EyePoint...
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
August 30, 2023 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the...
EyePoint Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
August 09, 2023 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., Aug. 09, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients...
EyePoint Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Corporate Developments
August 02, 2023 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
–Phase 2 DAVIO 2 clinical trial evaluating EYP-1901 in wet age-related macular degeneration remains on track to report topline data in December 2023 – –Phase 2 PAVIA clinical trial evaluating...
EyePoint Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 2, 2023
July 26, 2023 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., July 26, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients...
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 17, 2023 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
WATERTOWN, Mass., July 17, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve...
EyePoint Pharmaceuticals Announces Chief Executive Officer Transition
July 10, 2023 07:00 ET
|
EyePoint Pharmaceuticals, Inc.
– Jay S. Duker, M.D., Previously President and Chief Operating Officer, Appointed President and Chief Executive Officer – – Nancy S. Lurker Transitions to Executive Vice Chair of the Board of...